Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LS-ABMSC1 Autologous Bone Marrow Mesenchymal Stem Cells in Decompensated Liver Cirrhosis
jRCT2063200014Phase 2Active, not recruiting
- Sponsor
- Shibuya Corporation
- Start
- May 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LS-ABMSC1 in Cirrhosis, sponsored by Shibuya Corporation. Primary endpoint: Safety (adverse events). Started May 2021; status: active, not recruiting.
02
Drugs
LS-ABMSC1
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCT2063200014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063200014.